An article in the Nov. 10, 1998, issue of BioWorld Today should have said Gilead Sciences Inc. reported favorable results in a Phase II trial of adefovir dipivoxil for hepatitis B. Phase III trials are expected to begin early next year. Separately, the company expects to file a new drug application for the company's HIV drug, Preveon, is expected in the first half of 1999 and will be based on the pivotal study GS 408. Complementary studies in HIV were GS 417 and GS 420.

No Comments